tiprankstipranks

Theriva Biologics Advances VCN-01 with FDA Guidance

Protect Your Portfolio Against Market Uncertainty

Theriva Biologics ( (TOVX) ) just unveiled an update.

Theriva Biologics announced key FDA guidance for a Phase 3 study of its cancer treatment VCN-01, following successful enrollment in a Phase 2b study. The FDA endorsed a stand-alone Phase 3 study design without additional chemotherapy, streamlining the path for advancing this promising therapy for metastatic pancreatic cancer. This decision aligns with Theriva’s strategy to offer new treatment options in areas of high unmet need.

Find detailed analytics on TOVX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App